ClinicalTrials.gg

Anemia, Hemolytic, Autoimmune clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 103 studies for Anemia, Hemolytic, Autoimmune across more than 10 countries. 39 are recruiting or about to start. 79 of them are mainly about Anemia, Hemolytic, Autoimmune (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
31
Recruiting
24
Not yet recruiting
14
Active, not recruiting
11
Terminated
9
Status unknown
8

Phase

Phase 2
36
Phase 1
25
Phase 3
16
Early Phase 1
9
Phase 4
1

Where

China
39
United States
31
Italy
22
Germany
18
United Kingdom
18
France
18

Who develops what

Add Anemia, Hemolytic, Autoimmune to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 10 programs from 9 companies, 6 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bristol-Myers Squibb, Grit Biotechnology and Keymed Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabine phosphateRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07603557 · Bristol-Myers Squibb · Phase 2 · live · background · “Fludarabine Phosphate” · registered May 2026
Sanofi50% of its industry studies11 study
CyclophosphamideRecent, limited
Evidence
  • NCT07603557 · Bristol-Myers Squibb · Phase 2 · live · background · “Cyclophosphamide” · registered May 2026
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
rilzabrutinibApproved: US 2025 · EU 2025☆ Track1 live phase-3 study: NCT07086976Sanofi

The 1 in phase 3 with the nearest primary completion, of 10 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 18 Nov 2027 est.CM336 · Keymed Biosciences Co.Ltd · Phase 2 named, not the main aimNCT07175493 A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia — primary endpoint: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) · 158 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Anemia, Hemolytic, Autoimmune studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open

Coming up

17studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger. 5 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
105 (21%)5 (21%)
1823 (96%)23 (96%)
3023 (96%)23 (96%)
4023 (96%)23 (96%)
5023 (96%)23 (96%)
6522 (92%)22 (92%)
7519 (79%)19 (79%)
8514 (58%)14 (58%)

Across all 103 studies, recruiting or not: 26% stop at 75 or younger and 12% at 65; 22% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 103. Browse all 103 → or search them.